4.7 Article

Hypoxia drives transient site-specific copy gain and drug-resistant gene expression

Journal

GENES & DEVELOPMENT
Volume 29, Issue 10, Pages 1018-1031

Publisher

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.259796.115

Keywords

CNV; JmjC; KDM4A; hypoxia; site-specific copy gain; tumor heterogeneity

Funding

  1. American Cancer Society [RSG-13-115-01-CCG, CA059267, R01GM097360]
  2. American Lung Association Lung Cancer Discovery Award
  3. National Institutes of Health [U24CA143845]
  4. Massachusetts General Hospital Executive Committee on Research (ECOR) Tosteson Post-doctoral Fellowship
  5. Senior Research Training Fellowship from the American Lung Association
  6. Fund for Medical Discovery
  7. Marsha Rivkin Center for Ovarian Cancer Research
  8. National Sciences and Engineering Research Council of Canada
  9. National Institutes of Health Director's Pioneer Award [DP1 GM105378]
  10. Jim and Ann Orr Research Scholar Award
  11. AbbVie
  12. Canada Foundation for Innovation (CFI)
  13. Canadian Institutes of Health Research (CIHR)
  14. Genome Canada
  15. Ontario Genomics Institute [OGI-055]
  16. GlaxoSmithKline
  17. Novartis Research Foundation
  18. Ontario Ministry of Economic Development and Innovation
  19. Pfizer
  20. Structural Genomics Consortium
  21. Jane Coffin Childs Memorial Fund for Medical Research
  22. Boehringer Ingelheim
  23. Janssen
  24. Lilly Canada
  25. Takeda
  26. Wellcome Trust [092809/Z/10/Z]
  27. [1RO1CA160458]

Ask authors/readers for more resources

Copy number heterogeneity is a prominent feature within tumors. The molecular basis for this heterogeneity remains poorly characterized. Here, we demonstrate that hypoxia induces transient site-specific copy gains (TSSGs) in primary, nontransformed, and transformed human cells. Hypoxia-driven copy gains are not dependent on HIF1 alpha or HIF2 alpha; however, they are dependent on the KDM4A histone demethylase and are blocked by inhibition of KDM4A with a small molecule or the natural metabolite succinate. Furthermore, this response is conserved at a syntenic region in zebrafish cells. Regions with site-specific copy gain are also enriched for amplifications in hypoxic primary tumors. These tumors exhibited amplification and overexpression of the drug resistance gene CKS1B, which we recapitulated in hypoxic breast cancer cells. Our results demonstrate that hypoxia provides a biological stimulus to create transient site-specific copy alterations that could result in heterogeneity within tumors and cell populations. These findings have major implications in our understanding of copy number heterogeneity and the emergence of drug resistance genes in cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available